<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00668707</url>
  </required_header>
  <id_info>
    <org_study_id>2007077-01H</org_study_id>
    <nct_id>NCT00668707</nct_id>
  </id_info>
  <brief_title>Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality</brief_title>
  <acronym>AMPLCaRe</acronym>
  <official_title>Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality: A Randomized Placebo Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Canadian College of Naturopathic Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Ottawa Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lotte &amp; John Hecht Memorial Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gateway for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Canadian College of Naturopathic Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is evidence to support the use of melatonin, a natural health product, as an additional&#xD;
      treatment aid for cancer patients. This study is designed to see if the daily ingestion of 20&#xD;
      milligrams of melatonin for one year can lower the incidence of developing lung cancer&#xD;
      recurrence and/or death. Only patients with a diagnosis of non small cell lung cancer who are&#xD;
      eligible for surgical resection can participate in the trial. The study will also be&#xD;
      assessing for changes in quality of life, pain, fatigue, anxiety, sleep, and depression&#xD;
      amongst the participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial employs a two-armed parallel placebo controlled trial design whereby patients with&#xD;
      a diagnosis of non small cell lung cancer are randomized to receive either 20 mg of melatonin&#xD;
      nightly or an identically matched placebo. All patients will be followed for two years with&#xD;
      primary outcomes assessed at a two year time point and secondary outcomes evaluated&#xD;
      throughout the course of the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">November 30, 2017</completion_date>
  <primary_completion_date type="Actual">March 9, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lung Cancer Recurrence or Mortality - 2 Years</measure>
    <time_frame>2 years</time_frame>
    <description>Disease-Free survival (DFS) at 2 years post-surgery. DFS is measured by the number of participants in both arms who have experienced a recurrence OR mortality at 2 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>2 years</time_frame>
    <description>Participant-reported quality of life using the European Organization for Research and Treatment of Cancer's Quality of Life Questionnaire C-30 (EORTC QLQ C-30) and Lung Cancer 13 (EORTC QLQ LC13) questionnaires. Scores represent a value from 0-100. Symptom and LC13 scale: 0 represents best health, 100 worst health. Global and functional scales: 100 represents best health, 0 represents worst health. Full scoring algorithms available here: https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>2 years</time_frame>
    <description>Measured using the Multidimensional Fatigue Inventory 20 (MFI-20) questionnaire. Scores are on a scale of 0-100, where 100 is the best health and 0 is the worst health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep</measure>
    <time_frame>2 years</time_frame>
    <description>Measured using the Medical Outcomes Study (MOS) Sleep Survey. Scales used were Sleep Adequacy and Sleep problems Index II. Scores are on a scale of 0-100. Sleep Adequacy: 100 represents best health; 0 represents worst health. Problems index: 0 represents best health; 100 represents worst health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Levels</measure>
    <time_frame>3 months</time_frame>
    <description>Calculated using the Brief Pain Inventory. Each scale ranges from 0-10, where 0 is no pain and 10 is the worst possible pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>2 years</time_frame>
    <description>Measured using the Beck Anxiety Inventory. Scored range from 0-63, where 0 is no anxiety and 63 is the worst possible anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>2 years</time_frame>
    <description>Measured using the Beck Depression Inventory II. Scores range from 0-63, where 0 is no depression and 63 is the worst possible depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (Chemotherapy)</measure>
    <time_frame>2 years</time_frame>
    <description>Number of participants who experienced an adverse event related to their adjuvant chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Cancer Recurrence or Mortality - 5 Years</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Measured as disease-free survival (DFS) at 5 years. DFS was measured by the incidence of a recurrence OR mortality up to 5 years post-surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Tests to Examine the Effects of Melatonin on the Immune System (Raw Values)</measure>
    <time_frame>6 months</time_frame>
    <description>NK cell cytotoxicity changes from baseline to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (Radiation)</measure>
    <time_frame>2 years</time_frame>
    <description>Number of participants who experienced an adverse event related to their adjuvant radiation therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Tests to Examine the Effects of Melatonin on the Immune System (Comparison Between Groups)</measure>
    <time_frame>6 months</time_frame>
    <description>Differences in NK cell cytotoxicity between both arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">709</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To receive 20 mg of melatonin nightly for 1 year post-surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>To receive 20 mg placebo nightly for 1 year post-surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>melatonin</intervention_name>
    <description>20 mgs ingested nightly</description>
    <arm_group_label>Melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>similar to experimental in all ways except for lack of active ingredient</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of non small cell lung cancer&#xD;
&#xD;
          -  Eligible for surgical resection&#xD;
&#xD;
          -  Willingness to adhere to randomized treatment&#xD;
&#xD;
          -  Availability for follow-up schedule of visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Taking exogenous melatonin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dugald MR Seely, ND, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Canadian College of Naturopathic Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew JE Seely, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ottawa Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kelowna General Hospital</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 4N7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fraser Health</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 7P8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Centre/Capital Health</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's/ McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5C1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa General Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 1J7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Qu√©bec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.ccnm.edu</url>
    <description>The Canadian College of Naturopathic Medicine</description>
  </link>
  <reference>
    <citation>Mills E, Wu P, Seely D, Guyatt G. Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res. 2005 Nov;39(4):360-6. Review.</citation>
    <PMID>16207291</PMID>
  </reference>
  <reference>
    <citation>Seely D, Wu P, Fritz H, Kennedy DA, Tsui T, Seely AJ, Mills E. Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Integr Cancer Ther. 2012 Dec;11(4):293-303. doi: 10.1177/1534735411425484. Epub 2011 Oct 21. Review.</citation>
    <PMID>22019490</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 25, 2008</study_first_submitted>
  <study_first_submitted_qc>April 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2008</study_first_posted>
  <results_first_submitted>March 8, 2021</results_first_submitted>
  <results_first_submitted_qc>July 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 3, 2021</results_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melatonin</keyword>
  <keyword>natural health product (NHP)</keyword>
  <keyword>lung cancer</keyword>
  <keyword>complementary and alternative medicine (CAM)</keyword>
  <keyword>randomized clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 8, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT00668707/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>To receive 20 mg of melatonin nightly for 1 year&#xD;
melatonin: 20 mg ingested nightly</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>To receive matched supplement to the experimental arm in same schedule&#xD;
placebo: similar to experimental in all ways except for lack of active ingredient</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="356"/>
                <participants group_id="P2" count="353"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="173"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="199"/>
                <participants group_id="P2" count="180"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Cancer Recurrence</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>To receive 20 mg of melatonin nightly for 1 year&#xD;
melatonin: 20 mgs ingested nightly</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>To receive matched supplement to the experimental arm in same schedule&#xD;
placebo: similar to experimental in all ways except for lack of active ingredient</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="356"/>
            <count group_id="B2" value="353"/>
            <count group_id="B3" value="709"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.2" spread="8.5"/>
                    <measurement group_id="B2" value="67.2" spread="8.6"/>
                    <measurement group_id="B3" value="67.2" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="190"/>
                    <measurement group_id="B2" value="208"/>
                    <measurement group_id="B3" value="398"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-Operative Chemotherapy or Radiation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking History</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Current Smoker</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Past Smoker</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="279"/>
                    <measurement group_id="B2" value="263"/>
                    <measurement group_id="B3" value="542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never Smoked</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histological Subtype</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Squamous Cell</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adenocarcinoma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                    <measurement group_id="B2" value="239"/>
                    <measurement group_id="B3" value="468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Large Cell</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronchoalveolar</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Undifferentiated</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Surgical</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Incision Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Minimally Invasive Surgery (MIS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="213"/>
                    <measurement group_id="B2" value="212"/>
                    <measurement group_id="B3" value="425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIS Converted to Open</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Open</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Surgical</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgery Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Pneumonectomy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lobectomy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="290"/>
                    <measurement group_id="B2" value="284"/>
                    <measurement group_id="B3" value="574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segmentectomy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wedge Resection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Operation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pathological Cancer Stage</title>
          <description>Overall 7th Edition American Joint Committee on Cancer (AJCC) stage (I-IV) based on the TNM classification. T refers to tumor size, N refers to nearby lymph nodes and M represents metastasized (spread) to other parts of the body. This staging number is obtained as a sum of the TNM classification. The lower the number, the lower the cancer stage and the better the prognosis for the patient. The higher the stage, the worse the prognosis.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Stage I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="245"/>
                    <measurement group_id="B2" value="217"/>
                    <measurement group_id="B3" value="462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage II</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage III</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage IV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Surgical</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                    <count group_id="B2" value="353"/>
                    <count group_id="B3" value="709"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lung Cancer Recurrence or Mortality - 2 Years</title>
        <description>Disease-Free survival (DFS) at 2 years post-surgery. DFS is measured by the number of participants in both arms who have experienced a recurrence OR mortality at 2 years.</description>
        <time_frame>2 years</time_frame>
        <population>Intention to treat - all participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>To receive 20 mg of melatonin nightly for 1 year following surgery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>To receive 20 mg placebo nightly for 1 year following surgery&#xD;
placebo: similar to experimental in all ways except for lack of active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Cancer Recurrence or Mortality - 2 Years</title>
          <description>Disease-Free survival (DFS) at 2 years post-surgery. DFS is measured by the number of participants in both arms who have experienced a recurrence OR mortality at 2 years.</description>
          <population>Intention to treat - all participants analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="356"/>
                <count group_id="O2" value="353"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis conducted was an adjusted logistic regression (adjuvant chemotherapy, adjuvant radiation, smoking history). Results were presented as a relative risk. Based on an estimated 30% outcome rate of recurrence or mortality in the control arm, 294 participants per arm provided 80% power to detect a relative risk of one third at an alpha of 0.05. We inflated this sample size to 346 per arm to account for 15% lost to follow-up.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.94</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <description>Participant-reported quality of life using the European Organization for Research and Treatment of Cancer's Quality of Life Questionnaire C-30 (EORTC QLQ C-30) and Lung Cancer 13 (EORTC QLQ LC13) questionnaires. Scores represent a value from 0-100. Symptom and LC13 scale: 0 represents best health, 100 worst health. Global and functional scales: 100 represents best health, 0 represents worst health. Full scoring algorithms available here: https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf</description>
        <time_frame>2 years</time_frame>
        <population>Intention to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>To receive 20 mg of melatonin nightly for 1 year post surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>To receive 20 mg placebo nightly for 1 year post surgery&#xD;
placebo: similar to experimental in all ways except for lack of active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <description>Participant-reported quality of life using the European Organization for Research and Treatment of Cancer's Quality of Life Questionnaire C-30 (EORTC QLQ C-30) and Lung Cancer 13 (EORTC QLQ LC13) questionnaires. Scores represent a value from 0-100. Symptom and LC13 scale: 0 represents best health, 100 worst health. Global and functional scales: 100 represents best health, 0 represents worst health. Full scoring algorithms available here: https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf</description>
          <population>Intention to Treat</population>
          <units>Score on a scale of 0-100</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="356"/>
                <count group_id="O2" value="353"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Symptom Scale (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="19.1" upper_limit="23.7"/>
                    <measurement group_id="O2" value="20.3" lower_limit="18.0" upper_limit="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom Scale (1Y)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="15.7" upper_limit="20.7"/>
                    <measurement group_id="O2" value="17.0" lower_limit="14.3" upper_limit="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom Scale (2Y)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="14.6" upper_limit="20.0"/>
                    <measurement group_id="O2" value="15.8" lower_limit="13.2" upper_limit="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Functional Scale (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.8" lower_limit="73.2" upper_limit="78.5"/>
                    <measurement group_id="O2" value="75.5" lower_limit="72.9" upper_limit="78.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Functional Scale (1Y)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.9" lower_limit="77.0" upper_limit="82.8"/>
                    <measurement group_id="O2" value="81.1" lower_limit="78.2" upper_limit="84.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Functional Scale (2Y)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2" lower_limit="77.0" upper_limit="83.3"/>
                    <measurement group_id="O2" value="80.5" lower_limit="77.4" upper_limit="83.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global Scale (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.5" lower_limit="61.3" upper_limit="67.8"/>
                    <measurement group_id="O2" value="62.7" lower_limit="59.5" upper_limit="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global Scale (1Y)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" lower_limit="65.9" upper_limit="73.3"/>
                    <measurement group_id="O2" value="71.6" lower_limit="67.9" upper_limit="75.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global Scale (2Y)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7" lower_limit="66.7" upper_limit="74.7"/>
                    <measurement group_id="O2" value="72.7" lower_limit="68.8" upper_limit="76.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LC13 Scale (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="15.3" upper_limit="19.4"/>
                    <measurement group_id="O2" value="19.0" lower_limit="17.0" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LC13 Scale (1Y)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" lower_limit="15.5" upper_limit="20.0"/>
                    <measurement group_id="O2" value="18.1" lower_limit="15.9" upper_limit="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LC13 Scale (2Y)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" lower_limit="14.7" upper_limit="19.5"/>
                    <measurement group_id="O2" value="17.5" lower_limit="15.2" upper_limit="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for the LC-13 scale.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Between-arm least squares mean difference in change from randomization to 24 months post-surgery represented the effect of the intervention.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for Symptom Scale.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.80</p_value>
            <p_value_desc>Between-arm least squares mean difference in change from randomization to 24 months post-surgery represented the effect of the intervention.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for Functional Scale.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.69</p_value>
            <p_value_desc>Between-arm least squares mean difference in change from randomization to 24 months post-surgery represented the effect of the intervention.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for Global Scale.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.11</p_value>
            <p_value_desc>Between-arm least squares mean difference in change from randomization to 24 months post-surgery represented the effect of the intervention.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.5</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fatigue</title>
        <description>Measured using the Multidimensional Fatigue Inventory 20 (MFI-20) questionnaire. Scores are on a scale of 0-100, where 100 is the best health and 0 is the worst health.</description>
        <time_frame>2 years</time_frame>
        <population>Intention to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>To receive 20 mg of melatonin nightly for 1 year post-surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>To receive 20 mg placebo nightly for 1 year post-surgery&#xD;
placebo: similar to experimental in all ways except for lack of active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Fatigue</title>
          <description>Measured using the Multidimensional Fatigue Inventory 20 (MFI-20) questionnaire. Scores are on a scale of 0-100, where 100 is the best health and 0 is the worst health.</description>
          <population>Intention to Treat</population>
          <units>Score on a scale of 0-100</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="356"/>
                <count group_id="O2" value="353"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8" lower_limit="56.3" upper_limit="62.9"/>
                    <measurement group_id="O2" value="57.0" lower_limit="53.8" upper_limit="60.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.4" lower_limit="57.9" upper_limit="64.9"/>
                    <measurement group_id="O2" value="62.4" lower_limit="58.9" upper_limit="65.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7" lower_limit="59.0" upper_limit="66.5"/>
                    <measurement group_id="O2" value="63.1" lower_limit="59.4" upper_limit="66.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between-arm least squares mean difference in change from randomization to 24 months post-surgery represented the effect of the intervention.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.2</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep</title>
        <description>Measured using the Medical Outcomes Study (MOS) Sleep Survey. Scales used were Sleep Adequacy and Sleep problems Index II. Scores are on a scale of 0-100. Sleep Adequacy: 100 represents best health; 0 represents worst health. Problems index: 0 represents best health; 100 represents worst health.</description>
        <time_frame>2 years</time_frame>
        <population>Intention to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>To receive 20 mg of melatonin nightly for 1 year post-surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>To receive 20 mg placebo nightly for 1 year post-surgery&#xD;
placebo: similar to experimental in all ways except for lack of active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep</title>
          <description>Measured using the Medical Outcomes Study (MOS) Sleep Survey. Scales used were Sleep Adequacy and Sleep problems Index II. Scores are on a scale of 0-100. Sleep Adequacy: 100 represents best health; 0 represents worst health. Problems index: 0 represents best health; 100 represents worst health.</description>
          <population>Intention to Treat</population>
          <units>Score on a scale of 0-100</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="356"/>
                <count group_id="O2" value="353"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sleep Adequacy (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.7" lower_limit="52.5" upper_limit="61.0"/>
                    <measurement group_id="O2" value="53.8" lower_limit="49.5" upper_limit="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Adequacy (1Y)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9" lower_limit="56.1" upper_limit="65.7"/>
                    <measurement group_id="O2" value="61.5" lower_limit="56.7" upper_limit="66.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Adequacy (2Y)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4" lower_limit="54.2" upper_limit="64.5"/>
                    <measurement group_id="O2" value="60.5" lower_limit="55.4" upper_limit="65.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Problems Index II (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7" lower_limit="29.9" upper_limit="35.6"/>
                    <measurement group_id="O2" value="33.6" lower_limit="30.8" upper_limit="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Problems Index II (1Y)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0" lower_limit="24.9" upper_limit="31.2"/>
                    <measurement group_id="O2" value="27.7" lower_limit="24.5" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Problems Index II (2Y)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" lower_limit="24.2" upper_limit="30.8"/>
                    <measurement group_id="O2" value="26.9" lower_limit="23.6" upper_limit="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sleep Adequacy Analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Between-arm least squares mean difference in change from randomization to 24 months post-surgery represented the effect of the intervention.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sleep problems index II analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.41</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Between-arm least squares mean difference in change from randomization to 24 months post-surgery represented the effect of the intervention.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>4.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Levels</title>
        <description>Calculated using the Brief Pain Inventory. Each scale ranges from 0-10, where 0 is no pain and 10 is the worst possible pain.</description>
        <time_frame>3 months</time_frame>
        <population>Only those recruited from the Ottawa Hospital were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>To receive 20 mg of melatonin nightly for 1 year following surgery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>To receive 20 mg placebo nightly for 1 year following surgery&#xD;
placebo: similar to experimental in all ways except for lack of active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Levels</title>
          <description>Calculated using the Brief Pain Inventory. Each scale ranges from 0-10, where 0 is no pain and 10 is the worst possible pain.</description>
          <population>Only those recruited from the Ottawa Hospital were included in this analysis.</population>
          <units>Score on a scale of 0-10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="2.4"/>
                    <measurement group_id="O2" value="2.3" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="2.1"/>
                    <measurement group_id="O2" value="2.4" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anxiety</title>
        <description>Measured using the Beck Anxiety Inventory. Scored range from 0-63, where 0 is no anxiety and 63 is the worst possible anxiety.</description>
        <time_frame>2 years</time_frame>
        <population>Only participants recruited from The Ottawa Hospital were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>To receive 20 mg of melatonin nightly for 1 year following surgery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>To receive 20 mg placebo nightly for 1 year following surgery&#xD;
placebo: similar to experimental in all ways except for lack of active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Anxiety</title>
          <description>Measured using the Beck Anxiety Inventory. Scored range from 0-63, where 0 is no anxiety and 63 is the worst possible anxiety.</description>
          <population>Only participants recruited from The Ottawa Hospital were included in the analysis.</population>
          <units>Score on a scale of 0-63</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="8.5"/>
                    <measurement group_id="O2" value="8.3" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="6.9"/>
                    <measurement group_id="O2" value="6.4" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depression</title>
        <description>Measured using the Beck Depression Inventory II. Scores range from 0-63, where 0 is no depression and 63 is the worst possible depression.</description>
        <time_frame>2 years</time_frame>
        <population>Only participants recruited from The Ottawa Hospital were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>To receive 20 mg of melatonin nightly for 1 year following surgery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>To receive 20 mg placebo nightly for 1 year following surgery&#xD;
placebo: similar to experimental in all ways except for lack of active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Depression</title>
          <description>Measured using the Beck Depression Inventory II. Scores range from 0-63, where 0 is no depression and 63 is the worst possible depression.</description>
          <population>Only participants recruited from The Ottawa Hospital were included in the analysis.</population>
          <units>Score on a scale of 0-63</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="7.2"/>
                    <measurement group_id="O2" value="8.6" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="5.9"/>
                    <measurement group_id="O2" value="7.7" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events (Chemotherapy)</title>
        <description>Number of participants who experienced an adverse event related to their adjuvant chemotherapy</description>
        <time_frame>2 years</time_frame>
        <population>Only those who received adjuvant chemotherapy were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>To receive 20 mg of melatonin nightly for 1 year post-surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>To receive 20 mg placebo nightly for 1 year post-surgery&#xD;
placebo: similar to experimental in all ways except for lack of active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (Chemotherapy)</title>
          <description>Number of participants who experienced an adverse event related to their adjuvant chemotherapy</description>
          <population>Only those who received adjuvant chemotherapy were included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Cancer Recurrence or Mortality - 5 Years</title>
        <description>Measured as disease-free survival (DFS) at 5 years. DFS was measured by the incidence of a recurrence OR mortality up to 5 years post-surgery.</description>
        <time_frame>up to 5 years</time_frame>
        <population>Intention to treat - all participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>To receive 20 mg of melatonin nightly for 1 year following surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>To receive 20 mg placebo nightly for 1 year following surgery&#xD;
placebo: similar to experimental in all ways except for lack of active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Cancer Recurrence or Mortality - 5 Years</title>
          <description>Measured as disease-free survival (DFS) at 5 years. DFS was measured by the incidence of a recurrence OR mortality up to 5 years post-surgery.</description>
          <population>Intention to treat - all participants analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="356"/>
                <count group_id="O2" value="353"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All participants</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="356"/>
                    <count group_id="O2" value="353"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early Stage Cancer</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="309"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Late Stage Cancer</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DFS up to five years post-surgery was compared using Kaplan-Meier curves and the log rank test, followed by a hazard ratio calculated using the Cox proportional hazard model adjusting for adjuvant chemotherapy, adjuvant radiation, and smoking history.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.41</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis included only those with stage I or II cancer (pathologic stage). DFS up to five years post-surgery was compared using Kaplan-Meier curves and the log rank test, followed by a hazard ratio calculated using the Cox proportional hazard model adjusting for adjuvant chemotherapy, adjuvant radiation, and smoking history.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis included only those participants who had stage III or IV cancer (pathologic stage). DFS up to five years post-surgery was compared using Kaplan-Meier curves and the log rank test, followed by a hazard ratio calculated using the Cox proportional hazard model adjusting for adjuvant chemotherapy, adjuvant radiation, and smoking history.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Tests to Examine the Effects of Melatonin on the Immune System (Raw Values)</title>
        <description>NK cell cytotoxicity changes from baseline to 6 months</description>
        <time_frame>6 months</time_frame>
        <population>Participants who qualified for the sub-study only.</population>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>To receive 20 mg of melatonin nightly for 1 year post-surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>To receive 20 mg placebo nightly for 1 year post-surgery&#xD;
placebo: similar to experimental in all ways except for lack of active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Tests to Examine the Effects of Melatonin on the Immune System (Raw Values)</title>
          <description>NK cell cytotoxicity changes from baseline to 6 months</description>
          <population>Participants who qualified for the sub-study only.</population>
          <units>Percent killing of K62 cells</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cytotoxicity (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.8" spread="3.6"/>
                    <measurement group_id="O2" value="42.7" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cytotoxicity (6 months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" spread="3.0"/>
                    <measurement group_id="O2" value="46.4" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis of melatonin changes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.21</ci_lower_limit>
            <ci_upper_limit>4.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of placebo changes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>7.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events (Radiation)</title>
        <description>Number of participants who experienced an adverse event related to their adjuvant radiation therapy</description>
        <time_frame>2 years</time_frame>
        <population>Only those who received adjuvant radiation were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>To receive 20 mg of melatonin nightly for 1 year post-surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>To receive 20 mg placebo nightly for 1 year post-surgery&#xD;
placebo: similar to experimental in all ways except for lack of active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (Radiation)</title>
          <description>Number of participants who experienced an adverse event related to their adjuvant radiation therapy</description>
          <population>Only those who received adjuvant radiation were included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Tests to Examine the Effects of Melatonin on the Immune System (Comparison Between Groups)</title>
        <description>Differences in NK cell cytotoxicity between both arms</description>
        <time_frame>6 months</time_frame>
        <population>Only those who were enrolled in the sub study and qualified for analysis were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>To receive 20 mg of melatonin nightly for 1 year following surgery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>To receive 20 mg placebo nightly for 1 year following surgery&#xD;
placebo: similar to experimental in all ways except for lack of active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Tests to Examine the Effects of Melatonin on the Immune System (Comparison Between Groups)</title>
          <description>Differences in NK cell cytotoxicity between both arms</description>
          <population>Only those who were enrolled in the sub study and qualified for analysis were included.</population>
          <units>Ratio of percent cytotoxicity</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.97" upper_limit="1.23"/>
                    <measurement group_id="O2" value="1.16" lower_limit="0.96" upper_limit="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis compares the mean ratios of 6 month cytotoxicity and baseline cytotoxicity between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 Years</time_frame>
      <desc>An adverse event is any untoward medical occurrence in a patient administered a medicinal product which does not necessarily have to have a causal relationship with this treatment. A serious adverse event is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or results in prolonging of existing hospitalization, results in a persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.</desc>
      <group_list>
        <group group_id="E1">
          <title>Melatonin</title>
          <description>To receive 20 mg of melatonin nightly for 1 year post-surgery</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>To receive 20 mg placebo nightly for 1 year post-surgery&#xD;
placebo: similar to experimental in all ways except for lack of active ingredient</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Aortic Valve Replacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Apical thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>NSTEMI</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>STEMI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Left para-opthalmic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Retinal Tear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adbominal Abcess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Gall bladder removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Lower GI Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Perforated Bowel</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>SBO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Upper GI bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Chest Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Back sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Broken elbow</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Hip replacement surgery</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Left above-knee amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Left total knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Osteophyte fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Patella and fibular fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Shoulder Replacement Surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Toe Amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder Cancer Recurrence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>New Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>New Neoplasm - Bladder Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>New Neoplasm - Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>New Neoplasm - Colon Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>New Neoplasm - Lung Cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>New Neoplasm - Medullary carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>New Neoplasm - Pancreatic Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>New Neoplasm - Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>New Neoplasm - Skin Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>New Neoplasm - thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>New Neoplasm - thyroid nodule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>New Neoplasm - Urothelial Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Leptomeningeal disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Neuro-syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Renal Caliculi</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Bronchopleural fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>COPD Exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Hydropneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Prolonged Air Leak</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Subcutaneous Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Aneurism Surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Completion thyroidectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Resection of Liposarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Thoracotomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Total thyroidectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="184" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="166" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Blood/bone marrow - Other (myelotoxicity)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>ELevated AST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Elevated creatinine levels</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Elevated TNI</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Thrombic event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Atrial Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Cardiac - Intra-Op Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Cardiac Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Coronary Artery Calcification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Heart Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Thoracic Aortic Calcification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Hot swollen ears</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>ruptured eardrum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Burning eyes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Cataracts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>decreased vision in left eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Itchiness of eyes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Left eye pain (after starting chemo)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Vision changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Vitreous detachment/flashing lights</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal bloating</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Acid reflux</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Appetite changes</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Burping</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Dilaudid related withdrawal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>GERD</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Ileostomy reversal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Indigestion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Mouth Ulcers</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Thrush (mouth)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>UGI Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Ulcerative colitis flare up</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Costovertebral angle tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Desaturation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Fatgiue</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Generally unwell</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Hair loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Left vocal cord swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Loss of voice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Peripheral Edema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Ulcer on tongue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Voice hoarseness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gall bladder attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bladder infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>C-Difficile</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Chest infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Cold/Flu Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Fungal lung infection (Aspergillus)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Infectious Sebaceous Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Oral candida infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>pelvic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Shingles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Sinus infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Surgical site infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Throat Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Back of tongue pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Bone pain in upper thigh</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Burn marks (arm)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Burning sensation of feet, mostly at night</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Burning sensation when going to bathroom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Calf pain at night after starting chemo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Chronic pain/post-thoracotomy discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>elbow pain (left)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Erythema and tenderness arm, site of IV needle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Fracture - nose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Fracture - wrist</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Fractured foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Laceration - left fingers</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Left arm pain while on chemo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Left hand tingling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Left leg numbness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Left shoulder and neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>leg cramps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Leg/joint pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Lower back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pain (back)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pain (leg)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pain (ongoing issue from fibromyalgia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pain in left foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pain in right side (tender to touch)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pain in right side flank</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>pain left leg</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Postoperative Pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>R. Arm weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Right arm weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Severe stabbing pain in thighs</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Shoulder pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Sore back</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Sprained ankle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Surgical Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Swollen right hand (pain Rt 2 fingers)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Tenderness to incision site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Tooth Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>inflammatory pseudo tumor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>New Neoplasm - breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>New Neoplasm - Lung Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>New Neoplasm - Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>New Neoplasm - pancreatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>New Neoplasm - Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>New Neoplasm - Skin Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive dysfunction/loss of memory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Hyperarousal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Lighheadedness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>loss of balance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Memory difficulty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Migrane</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Peripheral Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Restlessness leg syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Spacey feeling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Spinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Subcostal neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Vivid Dreams</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fissures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>burning sensation when urinating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Difficulty Urinating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Frequent urination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>L. Kidney Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Discomfort or pain - breast area Rt side</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pain - right breast (dense feeling)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Prolapsed uterus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Ulceration vagina mucosa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Air Leak</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Aspiration pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Bonchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Burning sensation back of throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>COPD Exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Dry Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Fungal lung infection (Aspergillus)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Hemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Hiatal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Mucus in chest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pulmonary Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pulmonary Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Radiation pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Rib fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Separated rib</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Subcutaneous Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Increased thickness in nails</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Injection site reaction/extravasation changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Left vocal cord swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Sclera derma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>skin eruptions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Gall bladder removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark Legacy, Clinical Trial Coordinator</name_or_title>
      <organization>The Centre for Health Innovation</organization>
      <phone>613-792-1222 ext 1</phone>
      <email>mlegacy@thechi.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

